vandapharma.com (VNDA) Earnings growth forecast for next year

Vanda Pharmaceuticals (VNDA) possesses strong pricing power due to exclusive patents for its unique drug Hetlioz. Effective distribution through direct partners minimizes costs and ensures medication availability. The stability of mental health markets helps the company expand its patient base. The growth estimate for next year's EPS demonstrates a metric value of 70.80, which may indicate a search for strategic buyers.

Vanda (VNDA): Expected net earnings per share growth next year from 07/04/2022 to 11/15/2026

Analytical breakdowns and data insights for company Vanda Pharma (VNDA)

- share price and consensus valuation forecast:

Stock Price vandapharma.com|VNDA - Consensus Target

- market capitalization details:

Market Capitalization Vanda Pharmaceuticals Inc|VNDA - Value Adjusted for Debt and Cash

- book capitalization indicators:

Net Assets per Single Share Vanda Pharmaceuticals|VNDA - Total Stockholders' Equity|Market Cap to Net Assets Ratio vandapharma.com|VNDA - Aggregate Company Assets

- company total debt and liquidity indicators:

- net income and valuation ratios data:

VNDA - Final Profit|Expected Profit Vanda Pharmaceuticals|VNDA - Market Cap to Net Income|Forward P/E Multiple Vanda Pharmaceuticals Inc.|VNDA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Vanda Pharmaceuticals Inc.|VNDA - Operating profit EBITDA|Earnings per share for the last twelve months Vanda Pharmaceuticals|VNDA - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months vandapharma.com|VNDA - Net earnings per share growth this year|Earnings growth forecast for next year Vanda Pharmaceuticals

- total revenue and sales volume data:

VNDA - Revenue and Sales Volume|Projected Sales Volume vandapharma.com|VNDA - Market Cap to Revenue|Forward P/S Multiple Vanda Pharmaceuticals

General company analysis:Vanda Pharmaceuticals Inc., VNDA

Finished products of Vanda Pharmaceuticals Inc.

This indicator assesses the expected growth rate of earnings per share, reflecting the market consensus regarding future profitability. The calculation is based on aggregated analyst forecasts for future cash flows net of operating expenses. By analyzing the projected earnings per share trend for the coming year, an investor determines the business's capitalization potential. For Vanda Pharmaceuticals (VNDA), this growth depends on the efficiency of AI molecule screening while maintaining clinical trial costs.

Competing companies